[Articles] Yellow fever vaccination in healthy Gambian children of different ages to establish safety and immunogenicity of a booster dose: a open-label, non-randomised, single-site, phase 3 vaccine trial

The study investigated the safety and immunogenicity of a yellow fever booster vaccination in healthy children in Gambia. It was found that the booster vaccination was safe and elicited an immune response. Protective neutralising antibodies gradually waned after primary vaccination. The booster dose had a more pronounced effect in older children aged 4 to 9 years. In contrast, the effect was less pronounced in the youngest group of children aged 1 to 3 years. These findings can be valuable for policymakers. They will help determine the need and optimal timing of yellow fever booster vaccination in children in endemic areas.